Director Buys $50K in Shares at Significant Premium, Following Recent Private Placement
CTRVP is trading near its 52-week low of $0.001 (0.0% above the low).
Summary
A director of Hepion Pharmaceuticals purchased $50,000 in company stock at $0.04 per share, a price significantly higher than the current market, signaling strong insider confidence following a recent private placement.
Key Events · Ownership and Investor Activity · CTRVP
-
Director's Significant Purchase
Director Appajosyula Sireesh acquired 1,250,000 shares of common stock for $50,000 in an open market transaction on April 21, 2026.
-
Premium Price Paid
The shares were purchased at $0.04 each, which is substantially higher than the current market price of $0.0013, indicating strong conviction.
-
Link to Recent Private Placement
This purchase aligns with a $700,000 private placement announced on April 22, 2026, where shares were also sold at $0.04, suggesting the director's participation or related investment.
Analysis · CTRVP · Life Sciences
A director of Hepion Pharmaceuticals, Sireesh Appajosyula, made a substantial open market purchase of $50,000 worth of common stock. This transaction is particularly notable as the shares were acquired at $0.04 each, a price significantly above the current market price of $0.0013. This purchase likely relates to the $700,000 private placement disclosed on April 22, 2026, which also priced shares at $0.04. The director's willingness to invest at such a premium demonstrates strong conviction in the company's future prospects, especially given the recent capital raise.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $476.4K. The 52-week trading range was $0.00 to $0.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.